Clinical Trials Logo

Enteral Nutrition clinical trials

View clinical trials related to Enteral Nutrition.

Filter by:

NCT ID: NCT02779335 Completed - Enteral Nutrition Clinical Trials

Enteral Formula Tolerance in Pediatric Patients

Start date: May 2016
Phase: N/A
Study type: Interventional

The purpose of this prospective study seeks to assess ability to achieve enteral feeding goals with standard polymeric enteral formula in a stable, pediatric tube-fed population.

NCT ID: NCT02724631 Active, not recruiting - Enteral Nutrition Clinical Trials

TubeClear® Evaluation in Pediatric Patients (Phase I)

Start date: November 2016
Phase: N/A
Study type: Interventional

This is the first of three planned phases designed to evaluate the feasibility and tolerability of TubeClear® to restore patency in occluded Pediatric Enteral Access Devices. Based on preliminary data obtained from this phase of the study, subsequent phases will continue to evaluate feasibility and tolerability (Phase IIA) and ultimately compare efficacy of TubeClear® to the Children's Hospital of Philadelphia (CHOP) Standard Treatment to restore patency in occluded Pediatric Enteral Access Devices (EAD) (Phase IIB).

NCT ID: NCT02598375 Recruiting - Enteral Nutrition Clinical Trials

Evaluation of Status of Early Reached Target Enteral Nutrition and IFABP as Biomarker of Feeding Intolerance in Critically Ill Children

ERTENIFABPICU
Start date: January 2015
Phase: N/A
Study type: Observational [Patient Registry]

Stage 1 - Evaluation of Status of Early Reached Target Enteral Nutrition in critically ill children in the PICU (ERTEN in PICU). In critically ill children, there is no data on the factors influenced the enteral nutrition and feeding intolerance.The investigators aim to reach these goals in our study - To initiate the enteral feeding in pediatric intensive care units or not - To demonstrate the reasons whether early enteral feeding is initiated or not - To determine the incidence of feeding intolerance - To identify the situations such as analgesia ,sedation, catecholamines or individual preferences of the medical staff which lead to delay or interruption in enteral feeding in pediatric intensive care units - To investigate the relation between the successful enteral feeding and mortality , morbidity du to the sepsis , septic shock and multiorgan failure Stage 2 - IFABP as biomarker of feeding intolerance in critically ill children in the PICU (IFABP in PICU) Critically ill children are at increased risk for intestinal injury, gastrointestinal dysfunction and feeding intolerance, which are associated with delayed recovery and increased morbidity and mortality during their course in the pediatric intensive care unit. In critically ill children, there is little data on the factors influenced the enteral nutrition. We hypothesise that IFABP might be used as a biomarker which shows that the early intestinal damage due to these medications. Aim There is no information which shows that the role of the intestinal microcirculation problems and mucosal integrity on feeding intolerance in pediatric intensive care unit.We aim to reach these goals in our study - To show the value of IFABP regarding the identifying feeding intolerance and early detection of enteral feeding intolerance - To show the relation between the IFABP concentration and enteral feeding intolerance - To show the relation between the mechanical ventilation settings , sedation , inotropic medications doses and IFABP concentration and feeding intolerance - To show the relation between IFABP concentrations and mortality and morbidity due to the sepsis , septic shock and multi system organ failure Stage 1 (ERTEN in PICU) was completed . In many patients, initiation of feeding seems to be delayed without an evidence-based reason. ERTEN was achieved in 43 (25.3%) of 95 patients within 48 h after PICU admission. Patients with Early Initiation of Feeding were statistically significant more likely to have ERTEN. ERTEN was independent significant prognostic factors for survival (p<0.001), with reached target enteral caloric intake on day 2 indicating improved survival.

NCT ID: NCT02353689 Completed - Enteral Nutrition Clinical Trials

The Effect of FODMAP Content in Tube Feeding Formula on Feeding Intolerance and Nutritional Status Improvement

Start date: October 2013
Phase: Phase 2/Phase 3
Study type: Interventional

This study aimed to investigate the effects of FODMAP contents in enteral nutrition (EN) formulas on major gastrointestinal intolerance symptoms and nutritional status in tube fed patients through the randomized, double blind and placebo-controlled trial.

NCT ID: NCT02006953 Terminated - Enteral Nutrition Clinical Trials

Bolus Versus Continuous Feeding Regimens Post Gastrostomy Tube Placement

Start date: August 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the best way to feed children after they have a gastrostomy tube placed. The study compares bolus feeding to continuous feeding.

NCT ID: NCT01988792 Completed - Enteral Nutrition Clinical Trials

Human Milk Fortification in Very Low Birth Neonates

Start date: November 2013
Phase: N/A
Study type: Interventional

The purpose of this study to find out how safely we can add extra nutrients to human milk at different feeding volume.

NCT ID: NCT01307982 Completed - Clinical trials for Gastroesophageal Reflux

Comparative Anti-Reflux Procedures in Neurologically Impaired Children

CARPNIC
Start date: January 2011
Phase: N/A
Study type: Interventional

This trial is a randomized controlled trial of two standard anti-reflux procedures, Nissen fundoplication versus gastrojejunal feeding tubes (GJ tubes), in children and adolescents with functional and intellectual impairment who have gastrostomy feeding tubes and medically refractory or severe gastroesophageal reflux disease (GERD). This is a pilot study to establish feasibility before initiating a multi-centered study.

NCT ID: NCT01249963 Recruiting - Acute Pancreatitis Clinical Trials

Enteral Nutrition Product in Mild Acute Pancreatitis

Start date: February 2011
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the beneficial effects of the administration of enteral nutrition product with milk proteins, monounsaturated fatty acids and low dextrose equivalent maltodextrin and enriched in eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and medium chain triglycerides (MCT) in patients with mild acute pancreatitis. All this against other specific product. The main objectives of this project are: - Comparing the tolerance of both preparations. - Comparing the evolution of nutritional status in both groups. - Comparing the evolution of inflammatory parameters in both groups

NCT ID: NCT01233726 Completed - Critical Illness Clinical Trials

Effects of a Complete Diet in Critically Ill Patients With Stress Hyperglycemia

Start date: April 2010
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the beneficial effects of the administration of a complete diet rich in monounsaturated fatty acids and slow absorption carbohydrate in patients with stress hyperglycemia(T-Diet Plus Diabet IR). The main objective of this project is to evaluate blood glucose metabolic control, insulin requirements, insulin action resistance, lipid profile and to reduce infectious complications on mechanical ventilation ICU patients after the administration of a complete diet enriched in MUFA and slow absorption carbohydrates, without fructose.

NCT ID: NCT01025167 Completed - Enteral Nutrition Clinical Trials

The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients

Start date: September 2006
Phase: N/A
Study type: Interventional

The purpose of the study is to determine the impact of a specific nutrition formula with a high content of eicosapentaenoic acid (EPA) and fat in oncology patients receiving radio-/chemotherapy on body weight, body composition, nutritional status and physical function compared to a standard nutrition formula. Using an adaptive design approximately 80 patients will be randomized in the first part of the study. Following an interim analysis further 160 patients may be added, for a total of 240 patients.